TrialThe Lancet. Oncology2024

Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.

Abha A Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.